{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04868838",
            "orgStudyIdInfo": {
                "id": "20-010520"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Daratumumab to Treat Active Lupus Nephritis",
            "officialTitle": "A Mid-phase Open-label Trial Evaluating the Effectiveness and Safety of Daratumumab in Treatment of Patients With Active Kidney Involvement in Lupus",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "daratumumab-to-treat-active-lupus-nephritis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-04-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-20",
            "studyFirstSubmitQcDate": "2021-04-28",
            "studyFirstPostDateStruct": {
                "date": "2021-05-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Fernando Fervenza",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis."
        },
        "conditionsModule": {
            "conditions": [
                "Lupus Nephritis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Daratumumab",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects diagnosed with lupus nephritis will receive Daratumumab once weekly for 8 weeks and then once every 2 weeks for 8 additional does (+/- 4 days). Subjects will be followed for a total of 24 months (18 months after the last daratumumab administration).",
                    "interventionNames": [
                        "Drug: Daratumumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Daratumumab",
                    "description": "1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.",
                    "armGroupLabels": [
                        "Daratumumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Efficacy of daratumumab in inducing complete(CR) or partial(PR) renal remission in patients with active class III or IV Lupus Nephritis",
                    "description": "Complete Renal Response:- \\< 500 mg proteinuria/24 hours, Inactive urinary sediment (\\<10 RBC/HPF and absence of RBC casts), No greater than a 15% reduction in eGFR from enrollment",
                    "timeFrame": "12 months after first infusion of Daratumumab"
                },
                {
                    "measure": "Efficacy of daratumumab in inducing complete(CR) or partial(PR)",
                    "description": "Partial Renal Response: \\> 50% reduction in 24-hour proteinuria and proteinuria \\< 1g/24hr if baseline 24hr proteinuria, - \u22643 g/24hr and proteinuria \u2264 3 g/24hr if starting proteinuria \\> 3 g/24hrs. , Improved urinary sediment (\\>=50% reduction in RBC/HPF and absence of RBC casts), No greater than a 20% reduction in baseline eGFR",
                    "timeFrame": "12 months after first infusion of Daratumumab"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Safety of daratumumab in patients with active class III/IV LN.",
                    "description": "Incidence of major infections defined in the development of pneumonia, grade 3 urinary tract infection/pyelonephritis, sepsis, meningitis or anemia.",
                    "timeFrame": "24 months after first infusion of Daratumumab"
                },
                {
                    "measure": "Improvement from proteinuria",
                    "description": "Change in proteinuria in milligrams (mg) per 24h",
                    "timeFrame": "Baseline, 6, 12, 18 and 24 months after first infusion of Daratumumab"
                },
                {
                    "measure": "Change in hematuria.",
                    "description": "Improvement in hematuria from baseline as measured by the urinalysis",
                    "timeFrame": "Baseline,6, 12, 18 and 24 months after first infusion of Daratumumab"
                },
                {
                    "measure": "Improvement in eGFR",
                    "description": "Improvement in eGFR measured using the chronic kidney disease epidemiology collaboration (CKD-EPI) Equation: eGFR (CKD-EPI) = 141 x min(Scr/k, 1)alpha x max(Scr/k,1)-1.209 x 0.993age x 1.018 (if patient is female) x 1.159 (if patient is black)",
                    "timeFrame": "Baseline, 6, 12, 18 and 24 months after first infusion of Daratumumab"
                },
                {
                    "measure": "Change in ds-DNA",
                    "description": "Improvement in ds-DNA in International units per milliliter (IU/mL)",
                    "timeFrame": "Baseline, 6, 12, 18 and 24 months after first infusion of Daratumumab"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years of age.\n* Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria.\n* Renal biopsy confirming the diagnosis of active class III/IV (\u00b1 class V) LN (based on International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003) within 12 months of enrollment.\n* Proteinuria \u2265 500 mg over 24 hours.\n* eGFR \u2265 30 ml/min/SA.\n* Subjects should be able to give informed consent.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Hepatitis B or C, HIV\n* Anemia with Hgb \\< 8.0 g/dL.\n* Thrombocytopenia with platelet count \\< 100'000.\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication.\n* Unable to provide consent.\n* Patients receiving \\> 10 mg of oral prednisone or glucocorticoid equivalent if on corticosteroids for \\> 2 weeks (patients would be allowed to be on \\> 10 mg of prednisone or its oral equivalent as long as the duration is \u2264 2 weeks).\n* Patients who had received immunosuppressive therapy including cyclosporine, tacrolimus or azathioprine in the last 3 months.\n* Patients who have received cyclophosphamide in the last 6 months.\n* Patients who received rituximab previously with CD20 count of zero at the time of enrollment.\n* Patient are allowed to be on MMF at time of enrollment but no higher than total of 1500mg/day.\n* For women who are not postmenopausal (\u2265 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than (\\<) 1 percent (%) per year, during the treatment period and for at least 12 months after the last dose of study drug.\n* For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\< 1% per year during the treatment period and for at least 12 months after the last dose of study drug and agreement to refrain from donating sperm during this same period.\n* Patients with diagnosis of glaucoma.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nicholas Geroux",
                    "role": "CONTACT",
                    "phone": "507-266-0956",
                    "email": "geroux.nicholas@mayo.edu"
                },
                {
                    "name": "Corbyn Bendtsen",
                    "role": "CONTACT",
                    "phone": "507-284-0366",
                    "email": "bendtsen.corbyn@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Fernando Fervenza, MD",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic in Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nicholas Geroux",
                            "role": "CONTACT",
                            "phone": "507-266-0956",
                            "email": "geroux.nicholas@mayo.edu"
                        },
                        {
                            "name": "Corbyn Bendtsen",
                            "role": "CONTACT",
                            "phone": "507-284-0366",
                            "email": "bendtsen.corbyn@mayo.edu"
                        },
                        {
                            "name": "Ladan Zand, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Plan pending"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009393",
                    "term": "Nephritis"
                },
                {
                    "id": "D000008181",
                    "term": "Lupus Nephritis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000005921",
                    "term": "Glomerulonephritis"
                },
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12338",
                    "name": "Nephritis",
                    "asFound": "Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11178",
                    "name": "Lupus Nephritis",
                    "asFound": "Lupus Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9031",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3523",
                    "name": "Lupus Nephritis",
                    "asFound": "Lupus Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2525",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000556306",
                    "term": "Daratumumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M272211",
                    "name": "Daratumumab",
                    "asFound": "Kidney Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}